Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Bone Loss Prevention in Acute Stroke
NCT04652128Unknown
- Sponsor
- Yonsei University
- Start
- Jul 2019
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Randomised, double-blind trial of zoledronic acid in osteopenia and osteoporosis (2 arms), sponsored by Yonsei University. Primary endpoint: Bone mineral density at 12 months. Status: unknown.
02
Drugs
zoledronic acid
03
Conditions
osteopeniaosteoporosis
Beyond the preview
Go deeper on NCT04652128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652128.